Memorial Sloan Kettering presents CD371 IL-18 armored CAR T study at the American Society of Hematology annual meeting 2024 in San Diego. Tigen's Chief Business Officer Simon Eade is attending the presentation.

Tigen participated in the Swiss Innovation Challenge, a three-stage pitching contest, where we are thrilled to have made it to the final round. Collecting and integrating feedback from the broader ecosystem is part of our learning and growth journey. That's why we participate in incubation events and competitions. 

At Phacilitate Advanced Therapies Europe, Tigen's Diego Möckli presents and discusses access to breakthrough therapies, and how decentralizing and localizing development and manufacturing skills and capacity will create new opportunities for all the stakeholders in the cell and gene therapy ecosystem. 

Tigen presents AI enabled biomanufacturing platform for cell therapies to treat cancer at the Microsoft Ignite conference in Zurich, together with the digital innovation partners ELCA. 

Tigen signs option agreement with Memorial Sloan Kettering Cancer Center (MSK) for the autologous CD371 armored Chimeric Antigen Receptor (CAR) T-cell Technology to advance the

therapy development for relapsed/refractory Acute Myeloid Leukemia (AML).

Skills for Scientists meets Tigen at the Biopôle Lausanne - Academic vs. industrial career?

We were welcoming a group of PhD students, postdocs, and researchers from the University of Lausanne - UNIL and the CHUV | Lausanne university hospital in our Tigen office and lab and had an open and lively discussion about the life in academia vs. “the industry”.

Digital Innovation of the Year! Thanks to SwissICT for awarding this prestigious award to Tigen and ELCA Group for our digital platform to accelerate patient access to cell-based cancer therapies. Thanks also to Microsoft for being all-in. It’s an honor and motivation booster for our teams.

Tigen and the Swiss Data Science Center (SDSC) are joining forces to accelerate the AI engine that powers Tigen’s artificial intelligence-based biomanufacturing system for augmented cell & gene therapies. The project is supported by an Innosuisse grant from the Swiss government.

Tigen and ELCA collaborate on digital solutions to accelerate the development and supply of T cell-based cancer therapies. ELCA was awarded Microsoft Partner of the Year 2023, also based on our collaboration to advance digital healthcare.

Tigen and ELCA are shortlisted for the Digital Economy Award 2023, which is hosted by swissICT.

Our joint initiative «Digital Solution to advance T Cell-based Cancer Therapy Development» got recognition in the categories Digital Innovation of the Year and Digital Excellence. 

The International Society for Cell & Gene Therapy (ISCT) Paris 2023 conference was full of new insights and great conversations that led to many new contacts in the CGT ecosystem. Tigen's Ursula Busse presented our work on Next Generation TIL Therapies run together with CHUV and Ludwig Institute for Cancer Research.

We discovered some new sights of Lausanne last evening. The B2Run Schweizer Firmenlauf gathered an energetic crowd of athletes from small to large companies in the Stade de Pierre de Coubertin. 

Therese Choquette from the Tigen analytics team is sharing insights from our development work at the 2nd Cell Therapy Potency Assay Summit in Boston from May 31 - June 2, 2023.

We are curious to discuss with and learn from the CGT analytics community during the pre-conference workshop.

Tigen hosted the Cell & Gene Therapy panel at the Swiss Biotech Day 2023 in Basel. With thought leaders of our ecosystem, we discussed the disruptive opportunities to accelerate therapy development in Switzerland.

We were at DIA Europe 2023 in Basel discussing means to accelerate cell and gene therapy development.
While technical progress leads to a wide range of opportunities, the transformation of the wider ecosystem still requires a lot of concerted effort from all parties.

Tigen welcomes Michel Orsinger to the board of directors. As a global leader, Michel will support Tigen’s growth through his extensive healthcare and leadership experience.

Tigen exercises first option from the T Cell Program at the Centre hospitalier universitaire vaudois (CHUV) on behalf of the Ludwig Institute for Cancer Research for the development of a Neoantigen-specific Tumor Infiltrating Lymphocytes product (NeoTIL).

Join us in welcoming Simon Eade as Chief Business Officer.

Emily Whitehead Foundation, Bruce Levin and Stephan Grupp visiting the Tigen lab in Lausanne and discussing what's next in Cell & Gene Therapies.

Why we need a revolution for personalized cell therapies.

Join us in welcoming Simon Chaplin as Chief Financial Officer.

Dorothea Ledergerber discussing the future of cell & gene therapies manufacturing at the Advanced Therapies get-together in London.

Join us in welcoming Therese Choquette (Vallerskog) to the Tigen team as Head of Analytical Sciences.